Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22422290 | 1.00 | POLB (0.35) | POLBALDH1A1PDE7A | |
| Hydrochloric Acid SCHEMBL19126647 | 0.98 | POLB (0.34) | POLBALDH1A1PDE7A | |
| SCHEMBL1382368 | 0.98 | POLB (0.32) | POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL2173120 | 0.96 | POLB (0.33) | POLBALDH1A1PDE7A | |
| SCHEMBL20640397 | 0.93 | — | — | |
| SCHEMBL2516568 | 0.87 | — | — | |
| SCHEMBL2729918 | 0.79 | CRBN (0.34) | POLBALDH1A1PDE7A | |
| SCHEMBL340232 | 0.79 | NEK2 (0.38) | — | |
| SCHEMBL19094306 | 0.79 | HSD11B1 (0.30) | — | |
| SCHEMBL24535221 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114149413-A | 3- ((hetero) aryl) -8-amino-2-oxo-1, 3-aza-spiro- [4.5] -decane derivatives | 格吕伦塔尔有限公司 | 2022-03-08 | — | — | CN | claimed |
| EP-3402782-A1 | 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-11-21 | — | — | EP | claimed |
| EP-3402784-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-11-21 | — | — | EP | claimed |
| EP-3402785-A1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-11-21 | — | — | EP | claimed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | claimed |
| WO-2017121650-A1 | 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | claimed |
| WO-2017121649-A1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | claimed |
| WO-2017121648-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | claimed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | claimed |
| EP-2864309-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | Cadila Healthcare Limited (IN) | 2015-04-29 | — | — | EP | claimed |
| WO-2014002105-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2014-01-03 | — | — | WO | claimed |
| EP-1485057-B9 | DERIVATIVES OF AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN | SANOL ARZNEI SCHWARZ GMBH (DE) | 2006-06-28 | — | — | EP | claimed |
| EP-1485057-B1 | DERIVATIVES OF AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-12-28 | — | — | EP | claimed |
| US-20050119319-A1 | Derivatives of azaspiro compounds for the treatment of pain | SCHWARZ PHARMA AG (DE) | 2005-06-02 | — | — | US | claimed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| WO-2023244604-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-1485057-A2 | DERIVATIVES OF AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN | SCHWARZ PHARMA AG (DE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003073979-A2 | DERIVATIVES OF AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN | SCHWARZ PHARMA AG (DE) | 2003-09-12 | — | — | WO | disclosed |
| US-3979380-A | INOTROPIC ACTIVITY, CARDIAC STIMULANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | POLB 3547/4885ALDH1A1 3554/4885PDE7A 508/4885 |
| US-20050119319-A1 | Derivatives of azaspiro compounds for the treatment of pain | DDO, QDPR, CNR2 | POLB 4314/4885ALDH1A1 368/4885PDE7A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.